An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
Conditions
- Leukemia, Myeloid, Chronic
Interventions
Sponsor
King Faisal Specialist Hospital & Research Center